Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1993.11.1.59PMID 8418243
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A double-blind, crossover trial of intravenous clodronate in metastatic bone pain.

  1992cited by this paper
• Pathophysiology and Treatment of Paget's Disease of Bone

  1991cited by this paper
• Treatment of skeletal disease in breast cancer with clodronate.

  1991cited by this paper
• The Use of Clodronate in Disorders of Calcium and Skeletal Metabolism1

  1990cited by this paper
• The effect of compliance with treatment on survival among patients with hematologic malignancies.

  1990cited by this paper
• Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

  1990cited by this paper
• LONG‐TERM EFFECTS OF PARENTERAL DICHLOROMETHYLENE BISPHOSPHONATE (CL2MBP) ON BONE DISEASE OF MYELOMA PATIENTS TREATED WITH CHEMOTHERAPY

  1990cited by this paper
• Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.

  1989cited by this paper
• Clodronate for osteolytic metastases due to breast cancer.

  1988cited by this paper
• Bisphosphonates and bone metastases.

  1988cited by this paper
• Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.

  1988cited by this paper
• Bone metastases in breast cancer, prostate cancer and myeloma.

  1987cited by this paper
• Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.

  1987cited by this paper
• Bone metastases in breast cancer, prostate cancer and myeloma.

  1987cited by this paper
• Bone resorption and turnover in health and disease.

  1987cited by this paper
• Effects of intravenous etidronate disodium on skeletal and calcium metabolism.

  1987cited by this paper
• Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man.

  1987cited by this paper
• Treatment of the hypercalcaemia of malignancy with intravenous clodronate.

  1987cited by this paper
• Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.

  1986cited by this paper
• Mechanism of malignant hypercalcaemia in carcinoma of the breast.

  1985cited by this paper
• Intravenous etidronate in the management of malignant hypercalcemia.

  1985cited by this paper
• Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model.

  1984cited by this paper
• Use of dichloromethylene diphosphonate in metastatic bone disease.

  1983cited by this paper
• Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.

  1983cited by this paper
• Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma.

  1982cited by this paper
• Assessment of response and recurrence in breast cancer.

  1978cited by this paper
• Cyclophosphamide‐induced ovarian failure and its therapeutic significance in patients with breast cancer

  1977cited by this paper
• Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).

  1973cited by this paper
• New approach to the treatment of hypercalcemia The effect of short‐term treatment with mithramycin

  1971cited by this paper
• The management of pathological fracture of the major long bones from metastatic cancer.

  1958cited by this paper

• Timing of bone-modifying agents after bone metastasis diagnosis and time to first skeletal-related event: A systematic review and study-level correlation analysis.

  2025cites this paper
• Novel Approaches to Monitor Pharmacokinetics and Metabolism of Gemcitabine-Ibandronate Conjugate in Mice and Dogs

  2025cites this paper
• Brust- und gynäkologische Tumoren – medikamentöse Therapie ossärer Metastasen

  2023cites this paper
• Computed tomography density changes of bone metastases after concomitant denosumab

  2023cites this paper
• The 100 most cited papers on bone metastasis: A bibliometric analysis

  2022cites this paper
• Oligometastatic Disease in Non-Small-Cell Lung Cancer: An Update

  2022cites this paper
• Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases

  2022cites this paper
• Potential Adverse Effect of Nonsteroidal Anti‐Inflammatory Drugs (NSAIDs) on Bisphosphonate Efficacy: An Exploratory Post Hoc Analysis From a Randomized Controlled Trial of Clodronate

  2022cites this paper
• Liposome encapsulated clodronate mediated elimination of pathogenic macrophages and microglia: A promising pharmacological regime to defuse cytokine storm in COVID-19

  2022cites this paper
• Bone metastases—current status of bone-targeted treatments

  2022cites this paper
• "The use of bisphosphonates to treat skeletal complications in solid tumours".

  2021cites this paper
• Bone-modifying Agents (BMAs) in Breast Cancer.

  2021cites this paper
• MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

  2021cites this paper
• Management of bone metastases in renal cell carcinoma: bone-targeted treatments, systemic therapies, and radiotherapy

  2021cites this paper
• Bone Health in Cancer Patients

  2021cites this paper
• Review of Bone Modifying Agents in Metastatic Breast Cancer

  2021cites this paper
• How bone metastases can influence the management of breast cancer

  2021cites this paper
• Clodronate.

  2020cites this paper
• Bone metastases

  2020cites this paper
• Bisphosphonates and breast cancer - From cautious palliation to saving lives.

  2020cites this paper
• Chemistry of Bisphosphonates

  2020cites this paper
• Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study

  2019cites this paper
• Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307.

  2019cites this paper
• Adjuvant bisphosphonates or RANK-ligand inhibitors for patients with breast cancer and bone metastases: A systematic review and network meta-analysis.

  2019cites this paper
• Comparative effects of controlled release of sodium bicarbonate and doxorubicin on osteoblast and osteosarcoma cell viability.

  2019cites this paper
• Immunostimulants in Cancer Therapy

  2019cites this paper
• Prevention and Treatment of Skeletal Complications

  2019influential citation
• Role of Bisphosphonates in Breast Cancer Therapy

  2019cites this paper
• Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

  2019cites this paper
• Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

  2019cites this paper
• COMPARISON OF ORAL VERSUS INTRAVENOUS CLODRONATE IN PATIENTS WITH SKELETAL METASTASIS WITH RESPECT TO BONE MINERAL DENSITY AND PAIN SCORE

  2018cites this paper
• Meta-analysis of clodronate and breast cancer survival

  2018influential citation
• Bone-Modifying Agents and Anticancer Agents with Bone Effects

  2018cites this paper
• Bisphosphonates and other bone agents for breast cancer.

  2017cites this paper
• Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases.

  2017cites this paper
• Role of MAF in bone metastasis

  2017cites this paper
• Bone Modifier Use as Adjuvant Therapy for Early Breast Cancer

  2017cites this paper
• Biomaterial-Mediated Drug Delivery in Primary and Metastatic Cancers of the Bone

  2017cites this paper
• Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project

  2017cites this paper
• Optimal Use of Adjuvant Bisphosphonates and Breast Cancer.

  2017cites this paper
• Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.

  2016cites this paper
• Natural product derived immune-regulatory agents.

  2016cites this paper
• Bone targeted treatments in cancer – The story so far

  2016cites this paper
• Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?

  2016cites this paper
• Potential for Early Fracture Risk Assessment in Patients with Metastatic Bone Disease Using Parametric Response Mapping of CT Images

  2015cites this paper
• Bone metastases – current status of bone-targeted treatments

  2015cites this paper
• Traitements inhibiteurs de la résorption osseuse en situation métastatique : bilan actuel et perspectives

  2015cites this paper
• The role of bisphosphonates in early- and advanced-stage breast cancer: have we finally optimized care?

  2015cites this paper
• Bisphosphonates in breast cancer

  2015cites this paper
• Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma.

  2015cites this paper
• Clinical features of metastatic cancer in primary care: a case-control study using medical records.

  2015cites this paper
• Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases

  2015cites this paper
• Chapter 1. General introduction

  2015cites this paper
• Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.

  2015cites this paper
• Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy

  2015cites this paper
• Development of antibodies against the canine CSF-1R

  2015cites this paper
• The key role of bisphosphonates in the supportive care of cancer patients.

  2014cites this paper
• Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits

  2014cites this paper
• Профилактика развития костных метастазов при раке молочной железы

  2014cites this paper
• Effect of Clodronate Treatment on Risk of Fracture: A Systematic Review and Meta-analysis

  2014cites this paper
• On the Road to Personalized Medicine: Multiscale Computational Modeling of Bone Tissue

  2014cites this paper
• The effect of systemically and locally administered clodronate on bone quality

  2014cites this paper
• Forebyggelse af skeletrelaterede hændelser hos patienter med knoglemetastaser ved solide tumorer

  2014cites this paper
• Incidence and outcome of bone metastatic disease at University Malaya Medical Centre.

  2014cites this paper
• Systemic therapy of metastatic breast cancer

  2014cites this paper
• Moderne Osteoprotektion in der Onkologie

  2014cites this paper
• Bone health in cancer patients: ESMO Clinical Practice Guidelines.

  2014cites this paper
• Bisphosphonates in Bone Metastatic Setting

  2014cites this paper
• Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer

  2014cites this paper
• Knochenmetastasen bei gynäkologischen Malignomen

  2014cites this paper
• Medical treatment of breast cancer bone metastasis: from bisphosphonates to targeted drugs.

  2014cites this paper
• for palliative care Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines

  2014cites this paper
• Management of Metastatic Bone Disease in the Elderly with Bisphosphonates and RANKL Inhibitors: Effectiveness and Safety

  2014cites this paper
• Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.

  2013cites this paper
• Management of metastatic bone disease in the elderly with bisphosphonates and receptor activator of NF-kB ligand inhibitors: effectiveness and safety.

  2013cites this paper
• Treatment and prevention of bone metastases and myeloma bone disease

  2013cites this paper
• Improved Efficacy of Intramuscular Weekly Administration of Clodronate 200 mg (100 mg Twice Weekly) Compared with 100 mg (Once Weekly) for Increasing Bone Mineral Density in Postmenopausal Osteoporosis

  2013cites this paper
• Prevention and Treatment of Bone Metastases in Breast Cancer

  2013cites this paper
• Denosumab for treatment of bone metastases secondary to solid tumours: systematic review and network meta-analysis.

  2013cites this paper
• Bone metastases: assessment, management and treatment options.

  2013cites this paper
• Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone

  2013cites this paper
• Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

  2013cites this paper
• Comparative Efficacy of Bisphosphonates in Metastatic Breast and Prostate Cancer and Multiple Myeloma: A Mixed-Treatment Meta-analysis

  2013cites this paper
• Toxicity of Bone-Targeted Agents in Malignancy

  2013cites this paper
• Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases

  2013cites this paper
• Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors

  2012cites this paper
• Denosumab for treatment of breast cancer bone metastases and beyond

  2012cites this paper
• [Treatments of metastases in cancer].

  2012cites this paper
• Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes

  2012cites this paper
• Zoledronic Acid

  2012cites this paper
• Bisphosphonates and other bone agents for breast cancer.

  2012cites this paper
• Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates—Preliminary data

  2012cites this paper
• Bone health management in patients with breast cancer: current standards and emerging strategies.

  2012cites this paper
• The Clinical and Cost Considerations of Bisphosphonates in Preventing Bone Complications in Patients with Metastatic Breast Cancer or Multiple Myeloma

  2012influential citation
• The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer

  2012cites this paper
• Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.

  2012cites this paper
• Métastases osseuses : prise en charge multidisciplinaire, approche diagnostique et thérapeutique

  2012cites this paper
• Cancer du sein métastatique

  2012cites this paper
• Use of bisphosphonates in the management of patients with isolated bone metastases: results of a French survey

  2012cites this paper
• Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate

  2012cites this paper